NCT06597526 The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
| NCT ID | NCT06597526 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Peritoneal Metastasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-06-15 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-06-15 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions 2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction 3. Patients voluntarily enrolled in this study by signing an informed consent form 4. Age ≥ 18 years 5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2, 6. Expected life expectancy ≥ 3 months 7. Adequate organ and bone marrow function 8. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Signs of distant metastases other than peritoneal metastases at enrolment 2. Pregnant or breastfeeding women. 3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06597526 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Peritoneal Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06597526 currently recruiting?
Yes, NCT06597526 is actively recruiting participants. Contact the research team at jiajiahu@shsmu.edu.cn for enrollment information.
Where is the NCT06597526 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06597526 clinical trial?
NCT06597526 is sponsored by Ruijin Hospital. The trial plans to enroll 30 participants.